Disruption of hepatic lipid metabolic homeostasis leading to accumulation of toxic lipid species (ceramides, diacylglycerols, free cholesterol) that trigger insulin resistance, oxidative stress, inflammation, and fibrosis
Target Population
Adults with metabolic dysfunctions such as obesity, type 2 diabetes mellitus, hypertriglyceridemia, and metabolic syndrome
Care Setting
Chronic liver disease management in hepatology and metabolic clinics
Key Highlights
MAFLD is a multisystem disease strongly linked with metabolic dysfunction and cardiovascular comorbidities.
Hepatic lipid metabolites act as signaling molecules mediating insulin resistance and hepatocellular injury.
Therapeutic strategies are shifting towards targeting toxic lipid species and restoring lipid metabolic network balance.
Guideline-Based Recommendations
Diagnosis
Recognize MAFLD as a spectrum from simple steatosis to steatohepatitis and fibrosis linked to metabolic dysfunction.
Use clinical assessment of metabolic risk factors (obesity, diabetes, hypertriglyceridemia) alongside liver imaging and biomarkers.
Management
Focus on interventions targeting lipotoxic pathways and metabolic reprogramming.
Develop multi-target pharmacological approaches to selectively neutralize toxic lipid species while preserving physiological lipid functions.
Monitoring & Follow-up
Monitor progression from steatosis to steatohepatitis and fibrosis through clinical and biochemical markers.
Assess metabolic parameters and cardiovascular risk regularly due to multisystem involvement.
Risks
Increased risk of cardiovascular disease and extrahepatic malignancies in patients with MAFLD.
Progression to cirrhosis and hepatocellular carcinoma if metabolic and lipid dysregulation persist.
Patient & Prescribing Data
Adults with metabolic syndrome and MAFLD exhibiting hepatic lipid metabolic dysregulation
Emerging therapies aim to target specific toxic lipid species and restore hepatic lipid metabolic network balance; current pharmacological treatments remain limited and nonspecific.
Clinical Best Practices
Integrate metabolic risk factor management with liver disease treatment to address multisystem involvement.
Utilize advances in lipidomics and metabolomics to identify pathogenic lipid species for targeted therapy.
Adopt a network-based therapeutic approach focusing on restoring overall lipid metabolic homeostasis rather than isolated pathways.
